A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns

Transfusion

Volumn 49, Issue 6, 2009, Pages 1205-1216

  Goodrich, Raymond P ^a   Gilmour, Denise ^a   Hovenga, Nick ^a   Keil, Shawn D ^a  

^a CaridianBCT Biotechnologies LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN;

ARTICLE; BACTERIAL STRAIN; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; CONTROLLED STUDY; INTERMETHOD COMPARISON; LABORATORY TEST; SCREENING TEST; THROMBOCYTE; ULTRAVIOLET RADIATION;

BACTERIA; BLOOD PLATELETS; DISINFECTION; HUMANS; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 66549125829     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02126.x     Document Type: Article

References (53)

1. Yomtovian R, Lazarus HM, Goodnough LT, Hirschler NV, Morrissey AM, Jacobs MR. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993 33 : 902 9.
2. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematol Am Soc Hematol Educ Prog 2003 575 89.
3. Yomtovian RA, Palavecino EL, Dysktra AH, Downes KA, Morrissey AM, Bajaksouzian S, Pokorny MA, Lazarus HM, Jacobs MR. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 2006 46 : 719 30.
4. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, Jarvis WR. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001 41 : 1493 9.
5. Wagner SJ. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 2004 86 : 157 63.
6. AABB. Standards for blood banks and transfusion services. Bethesda (MD) : AABB 2004.
7. Fang CT, Chambers LA, Kennedy J, Strupp A, Fucci MC, Janas JA, Tang Y, Hapip CA, Lawrence TB, Dodd RY American Red Cross Regional Blood Centers. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion 2005 45 : 1845 52.
8. Holme S, Bunch C, Selman B. Bacterial contamination in stored platelets: performance of the Pall eBDS system under routine use conditions (P-194). Vox Sang 2005 89 Suppl 1 : 95.
9. Ramírez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M. Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion 2007 47 : 421 9.
10. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006 46 : 956 65.
11. Kleinman SH, Kamel HT, Harpool DR, Vanderpool SK, Custer B, Wiltbank TB, Nguyen KA, Tomasulo PA. Two-year experience with aerobic culturing of apheresis and whole blood-derived platelets. Transfusion 2006 46 : 1787 94.
12. Schrezenmeier H, Walther-Wenke G, Müller TH, Weinauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, Deitenbeck R, Förstemann E, Gebauer W, Höchsmann B, Karakassopoulos A, Liebscher UM, Sänger W, Schmidt M, Schunter F, Sireis W, Seifried E. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007 47 : 644 52.
13. Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ American Red Cross Regional Blood Centers. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007 47 : 1134 42.
14. Dumont L, Kleinman J, Murphy S, Lippincott J, Schuyler BR, Houghton J, Metzel P. Early screening of apheresis platelets reduces the risk of bacterially contaminated platelets - the PASSPORT study. Transfusion 2008 48 Suppl 3A.
15. Vostal JG. Update on FDA review of bacterial detection devices for a platelet release test indication and extension of platelet dating. [monograph on the Internet Washington, DC : U.S. Department of Health and Human Services 2005 cited August 12, 2005]. Available from: http://www.hhs.gov/ophs/bloodsafety/ presentations/may2005.html
16. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997 337 : 1861 9.
17. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation. The SPRINT Trial. Blood 2004 104 : 1534 41.
18. Goodrich RP, Edrich RA, Li J, Seghatchian J. The riboflavin and UV light system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35 : 5 17. (Pubitemid 44354317)
19. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003 101 : 2426 33.
20. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG SPRINT Study Group. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005 45 : 1864 75.
21. Mohr H, Redecker-Klein A. Inactivation of pathogens in platelet concentrates by using a two-step procedure. Vox Sang 2003 84 : 96 104. (Pubitemid 36565085)
22. Kumar V, Lockerbie O, Keil S, Ruane P, Platz M, Martin C, Ravanat J, Cadet J, Goodrich R. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004 80 : 15 21.
23. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev 2005 18 : 195 204. (Pubitemid 40170668)
24. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, Jarvis WR. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001 41 : 1493 9.
25. Perez P, Salmi LR, Follea G, Schmit JL, de Barbeyrac B, Sudre P, Salamon R BACTHEM Group; French Haemovigilance Network. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion 2001 41 : 862 72.
26. Love EM, Soldan K. The Serious Hazards of Transfusion Steering Group. SHOT Annual Report 2000-2001. London : The Serious Hazards of Transfusion Group 2002.
27. Castro E, Bueno JL, Barea L, Gonzalez R. Feasibility of implementing an automated culture system for bacteria screening in platelets in the blood bank routine. Transfus Med 2005 15 : 185 95.
28. Anderson KC, Lew MA, Gorgone BC, Martel J, Leamy CB, Sullivan B. Transfusion-related sepsis after prolonged platelet storage. Am J Med 1986 81 : 405 11.
29. Benjamin RJ, Dy BA, Kennedy JM, Eder AF. Frequent single bag bacterial contamination in split units of apheresis platelets suggests low concentrations at the time of sampling for quality control cultures and appreciable false negative detection rates. Transfusion 2007 47 Suppl : 37A.
30. Foley MJ, Doherty C, Salami A, Cadden E, Coakley P, Murphy WG. Resting platelet concentrates for bacterial contamination at day 4 prior to extended storage for 7 days. Transfusion 2007 47 Suppl : 37A.
31. Ruane P, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004 44 : 877 85.
32. Dumont LJ, AuBuchon JP, Whitley P, Herschel LH, Johnson A, McNeil D, Sawyer S, Roger JC. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002 42 : 847 54.
33. Diedrich B, Sandgren P, Jansson B, Gulliksson H, Svensson L, Shanwell A. In vitro and in vivo effects of potassium and magnesium on storage up to 7-days of apheresis platelet concentrates in platelet additive solution. Vox Sang 2008 94 : 96 102.
34. Shanwell A, Diedrich A, Falker C, Jansson B, Sandgren P, Sundkvist L, Svensson L, Vesterinen M, Gulliksson H. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days. Transfusion 2006 46 : 973 9.
35. Dijkstra-Tiekstra MJ, Pietersz RN, Hendriks EC, Reesink HW, Huijgens PC. In vivo PLT increments after transfusions of WBC-reduced PLT concentrates stored for up to 7 days. Transfusion 2004 44 : 330 6.
36. Kerkhoffs JL, Eikenboom JC, Schipperus MS, van Wordragen-Vlaswinkel RJ, Brand R, Harvery MS, de Vries RR, Barge R, van Rhenen DJ, Brand A. A multicenter randomized study of the efficacy of transfusion with platelets stored in platelet additive solution II versus plasma. Blood 2006 108 : 3210 5.
37. de Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk Kooy M, Bins M, van Prooijen HC. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000 40 : 398 403. (Pubitemid 30230501)
38. Li J, Goodrich L, Hansen E, Edrich R, Gampp D, Goodrich RP. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage. Transfusion 2005 45 : 1750 8.
39. AuBuchon JP, Snyder EL The rationale for a standardized approach to assessment of platelet kinetics. Transfusion 2006 46 : 44S 48S. (Pubitemid 44656907)
40. Goodrich R, Folléa G, Roberts T. Clinical evaluation of mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008 48 : 20a.
41. Pietersz RN, Engelfriet CP, Reesink HW, Wood EM, Winzar S, Keller AJ, Wilson JT, Henn G, Mayr WR, Ramirez-Arcos S, Goldman M, Georgsen J, Morel P, Herve P, Andeu G, Assal A, Seifried E, Schmidt M, Foley M, Doherty C, Coakley P, Salami A, Cadden E, Murphy WG, Satake M, de Korte D, Bosnes V, Kjeldsen-Kragh J, McDonald C, Brecher ME, Yomtovian R, AuBuchon JP. Detection of bacterial contamination of platelet concentrates. Vox Sang 2007 93 : 260 77.
42. Benjamin RJ, Wagner SJ. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion 2007 47 : 1381 9.
43. Kleinman SH, Kamel HT, Harpool DR, Vanderpool SK, Custer B, Wiltbank TB, Nguyen KA, Tomasulo PA. Two-year experience with aerobic culturing of apheresis and whole blood-derived platelets. Transfusion 2006 46 : 1787 94.
44. Silva MA, Gregory KR, Carr-Greer MA, Holmberg JA, Kuehnert MJ, Brecher ME Task Force. Summary of the AABB Interorganizational Task Force on Bacterial Contamination of Platelets: Fall 2004 impact survey. Transfusion 2006 46 : 636 41.
45. Yomtovian RA, Palavecino EL, Dysktra AH, Downes KA, Morrissey AM, Bajaksouzian S, Pokorny MA, Lazarus HM, Jacobs MR. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 2006 46 : 719 30.
46. Clawson CC, White JG. Platelet interaction with bacteria II. Fate of the bacteria. Am J Pathol 1971 65 : 381 95.
47. Nussbaumer W, Allersdorfer D, Grabmer C, Rheinschmidt M, Lin L, Schönitzer D, Lass-Flörl C. Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods. Transfusion 2007 47 : 1125 33.
48. Prowse C. Zero tolerance. Transfusion 2007 47 : 1106 9.
49. Fast LD, DiLeone GJ, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006 46 : 642 8.
50. Fast LD, DiLeone G, Carderelli G, Li J, Goodrich R. Riboflavin and UV light treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2/γc/double knockout mice. Transfusion 2006 46 : 1553 60.
51. Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006 90 : 85 91. (Pubitemid 43381495)
52. Rentas FJ, Harman R, Gomez C, Salata J, Childs J, Silva T, Lippert L, Montgomery J, Richards A, Chan C, Jiang J, Reddy H, Li J, Goodrich R. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007 47 : 240 7.
53. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007 84 : 1174 82.